'A sword of Damocles': patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study.

Autor:	Logeman C; School of Public Health, The University of Sydney, Sydney, New South Wales, Australia charlotte.logeman@sydney.edu.au.; Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales, Australia., Cho Y; Australasian Kidney Trials Network, University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia.; Department of Nephrology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Sautenet B; Department of Nephrology Hypertension, Centre Hospitalier Régional Universitaire de Tours, Tours, France., Rangan GK; Centre for Transplant and Renal Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.; Department of Renal Medicine, Westmead Hospital, Westmead, New South Wales, Australia., Gutman T; School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.; Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales, Australia., Craig J; College of Medicine and Public Health, Flinders University Faculty of Medicine, Nursing and Health Sciences, Adelaide, South Australia, Australia., Ong A; Academic Nephrology Unit, The Henry Wellcome Laboratories for Medical Research, University of Sheffield Medical School, Sheffield, UK., Chapman A; Department of Medicine, University of Chicago, Chicago, Illinois, USA., Ahn C; Internal Medicine, Seoul National University, Seoul, South Korea., Coolican H; Head Office, Polycystic Kidney Disease Foundation of Australia, Sydney, New South Wales, Australia., Tze-Wah Kao J; School of Medicine, Fu Jen Catholic University Hospital, New Taipei City, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Gansevoort RT; Faculty of Medical Sciences, University Medical Center Groningen, Groningen, The Netherlands., Perrone R; Division of Nephrology, Tufts University School of Medicine, Boston, Massachusetts, USA., Harris T; Head Office, PKD International, Geneva, Switzerland.; London Office, PKD International, London, UK., Torres V; Department of Nephrology and Hypertension, Mayo Clinic, Rochester, New York, USA., Fowler K; Kidney Health Initiative, The Voice of the Patient, Washington, DC, USA., Pei Y; Divisions of Nephrology and Genomic Medicine, University of Toronto, Toronto, Ontario, Canada., Kerr P; Nephrology, Monash Medical Centre Clayton, Melbourne, Victoria, Australia., Ryan J; Nephrology, Monash Medical Centre Clayton, Melbourne, Victoria, Australia., Johnson D; Department of Renal Medicine, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.; Australasian Kidney Trials Network, The University of Queensland, Saint Lucia, Queensland, Australia., Viecelli A; Australasian Kidney Trials Network, University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia.; School of Medicine, University of Queensland, Brisbane, Queensland, Australia., Geneste C; Department of Nephrology and Clinical Immunology, Centre Hospitalier Régional Universitaire de Tours, Tours, France., Kim H; Internal Medicine, Seoul National University Hospital, Jongno-gu, South Korea., Kim Y; Department of Internal Medicine, Keimyung University College of Medicine, Daegu, South Korea., Howell M; Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.; School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Ju A; School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.; Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales, Australia., Manera KE; School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.; Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales, Australia., Teixeira-Pinto A; School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.; Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales, Australia., Parasivam G; Discipline of Genetic Medicine, The University of Sydney Medical School, Sydney, New South Wales, Australia.; Clinical Genetics, The Sydney Children's Hospitals Network Randwick and Westmead, Westmead, New South Wales, Australia., Tong A; School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.; Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales, Australia.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2020 Oct 10; Vol. 10 (10), pp. e038005. Date of Electronic Publication: 2020 Oct 10.
DOI:	10.1136/bmjopen-2020-038005
Abstrakt:	Background and Objectives: Presymptomatic testing is available for early diagnosis of hereditary autosomal dominant polycystic kidney disease (ADPKD). However, the complex ethical and psychosocial implications can make decision-making challenging and require an understanding of patients' values, goals and priorities. This study aims to describe patient and caregiver beliefs and expectations regarding presymptomatic testing for ADPKD. Design, Setting and Participants: 154 participants (120 patients and 34 caregivers) aged 18 years and over from eight centres in Australia, France and Korea participated in 17 focus groups. Transcripts were analysed thematically. Results: We identified five themes: avoiding financial disadvantage (insecurity in the inability to obtain life insurance, limited work opportunities, financial burden); futility in uncertainty (erratic and diverse manifestations of disease limiting utility, taking preventive actions in vain, daunted by perplexity of results, unaware of risk of inheriting ADPKD); lacking autonomy and support in decisions (overwhelmed by ambiguous information, medicalising family planning, family pressures); seizing control of well-being (gaining confidence in early detection, allowing preparation for the future, reassurance in family resilience); and anticipating impact on quality of life (reassured by lack of symptoms, judging value of life with ADPKD). Conclusions: For patients with ADPKD, presymptomatic testing provides an opportunity to take ownership of their health through family planning and preventive measures. However, these decisions can be wrought with tensions and uncertainty about prognostic implications, and the psychosocial and financial burden of testing. Healthcare professionals should focus on genetic counselling, mental health and providing education to patients' families to support informed decision-making. Policymakers should consider the cost burden and risk of discrimination when informing government policies. Finally, patients are recommended to focus on self-care from an early age. Competing Interests: Competing interests: GKR declares he is site investigator of clinical trials sponsored by Sanofi, Otsuka and Reata, principal investigator of the PREVENT-ADPKD clinical trial (funded in part by the NHMRC, Danone Nutricia—manufacturer of bottled water—PKD Australia, Westmead Medical Research Foundation) and Chair, Scientific Advisory Board, PKD Australia. RP declares he is site investigator of clinical trials sponsored by Sanofi, Kadmon, Reata, Otsuka and the US Department of Defense (TAME PKD), and section editor for Cystic Kidney Disease, UpToDate. (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu